Skip to main content

Advertisement

SpringerLink
Log in

Quality of life in patients with progressive supranuclear palsy: one-year follow-up

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

The aim of this prospective cohort study that included 46 patients with progressive supranuclear palsy (PSP) was to estimate which demographic and clinical factors were the main contributors to the health-related quality of life (HRQoL) and how did the HRQoL change over a follow-up period of 1 year in these patients. The hierarchical regression analyses showed that the final models demonstrated that gender, included clinical variables and psychiatric/neuropsychological scales, accounted for 68 % of the variance in the Physical Composite Score and 73 % of the variance of the Mental Composite Score of the 36-item Short Form Health Survey (SF-36). Among variables in both final models, only the score of the Apathy Evaluation Scale showed statistically significant negative predictive value (p < 0.05). Changes in the HRQoL scores were assessed in 28 PSP patients who completed 1-year follow-up period after the baseline examination. Statistically significant decline in the HRQoL was detected for the following scales of the SF-36: physical functioning, vitality, social functioning, and role emotional, as well as in both composite scores (Physical Composite Score and Mental Composite Score). The analyses of magnitude of changes in the HRQoL during 1-year follow-up period showed large effect size (≥0.80) for total scores, as well as for the physical functioning, vitality, and social functioning. In conclusion, despite certain limitations, our study provided some new insights into potential predictors of the HRQoL and its longitudinal changes in patients with PSP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1–9

    Article  CAS  PubMed  Google Scholar 

  2. Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D, Hobart J (2006) Measuring quality of life in PSP. The PSP-QoL. Neurology 67(1):39–44

    Article  CAS  PubMed  Google Scholar 

  3. Brooks DJ (2002) Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 72(Suppl. 1):10–16

    Google Scholar 

  4. Wenning GK, Litvan I, Tolosa E (2011) Milestones in atypical and secondary parkinsonisms. Mov Disord 26(6):1083–1095

    Article  PubMed  Google Scholar 

  5. Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G, Quinn N (2004) Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 19(2):181–189

    Article  PubMed  Google Scholar 

  6. Higginson IJ, Gao W, Saleem TZ, Chaudhuri KR, Burman R, Mc Crone P, Leigh PN (2012) Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One 7(11):e46327

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Calvert M, Pall H, Hoppitt T, Eaton B, Savill E, Sackley C (2013) Health-related quality of life and supportive care in patients with rare long-term neurological conditions. Qual Life Res 22(6):1231–1238

    Article  PubMed  Google Scholar 

  8. Schrag A, Selai C, Davis J, Lees AJ, Jahanshahi M, Quinn N (2003) Health-related quality of life in patients with progressive supranuclear palsy. Mov Disord 18(12):1464–1469

    Article  PubMed  Google Scholar 

  9. Schrag A, Selai C, Quinn N, Hobart J (2005) Measuring health-related quality of life in patients with progressive supranuclear palsy. Neurocase 11(4):246–249

    Article  CAS  PubMed  Google Scholar 

  10. Schrag A, Sheikh S, Quinn NP, Lees AJ, Selai C, Mathias C, Litvan I, Lang AE, Bower JH, Burn DJ, Low P, Jahanshahi M (2010) A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 25(8):1077–1081

    Article  PubMed  Google Scholar 

  11. Winter Y, Spottke AE, Stamelou M, Cabanel N, Eggert K, Höglinger GU, Sixel-Doering F, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R (2011) Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis 8(6):438–446

    Article  PubMed  Google Scholar 

  12. Winter Y, Stamelou M, Cabanel N, Sixel-Döring F, Eggert K, Höglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE (2011) Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. J Neurol 258(10):1827–1834

    Article  PubMed  Google Scholar 

  13. Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, Kostic VS (2014) Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol 261(8):1575–1583

    Article  PubMed  Google Scholar 

  14. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442

    Article  CAS  PubMed  Google Scholar 

  15. Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(Pt6):1552–1565

    Article  PubMed  Google Scholar 

  16. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6(4):278–286

    Article  CAS  PubMed  Google Scholar 

  17. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32(1):50–55

    Article  CAS  PubMed  Google Scholar 

  18. Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the Apathy Evaluation Scale. Psychiat Res 38(2):143–162

    Article  CAS  Google Scholar 

  19. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308–2314

    Article  CAS  PubMed  Google Scholar 

  20. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR (2006) The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21(11):1078–1085

    Article  PubMed  Google Scholar 

  21. Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55(11):1621–1626

    Article  CAS  PubMed  Google Scholar 

  22. SF-36 Health Survey (Original version) Language Recalls. http://www.qualitymetric.com

  23. Ware JE, Snow KK, Kosinski M (1993) The SF-36 health survey manual and interpretation guide. Nimrod Press, Boston

    Google Scholar 

  24. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Academic Press, New York

    Google Scholar 

  25. Gerstenecker A, Duff K, Mast B, Litvan I, ENGENE-PSP Study Group (2013) Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res 210(3):1205–1210

    Article  PubMed  Google Scholar 

  26. Benito-León J, Cubo E, Coronell C, ANIMO Study Group (2012) Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov Disord 27(2):211–218

    Article  PubMed  Google Scholar 

  27. Aarsland D, Litvan I, Larsen JP (2001) Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13(1):42–49

    Article  CAS  PubMed  Google Scholar 

  28. Borroni B, Alberici A, Agosti C, Cosseddu M, Padovani A (2009) Pattern of behavioral disturbances in corticobasal degeneration syndrome and progressive supranuclear palsy. Int Psychogeriatr 21(3):463–468

    Article  PubMed  Google Scholar 

  29. Varanese S, Perfetti B, Ghilardi MF, Di Rocco A (2011) Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS One 6(3):e17846.3

    Article  Google Scholar 

  30. Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, Stuart GW, Currie J, Soo M, Olivieri G, Broe GA, Morris JG (2002) Frontal atrophy correlates with behavioral changes in progressive supranuclear palsy. Brain 125(Pt4):789–800

    Article  CAS  PubMed  Google Scholar 

  31. Agosta F, Galantucci S, Svetel M, Lukić MJ, Copetti M, Davidovic K, Tomić A, Spinelli EG, Kostić VS, Filippi M (2014) Clinical, cognitive, and behavioral correlates of white matter damage in progressive supranuclear palsy. J Neurol 261(5):913–924

    Article  PubMed  Google Scholar 

  32. Pedhazur EJ (1997) Multiple regression in behavioral research. Explanation and prediction. Wadsworth Publishing, Orlando

    Google Scholar 

  33. Meissner WG, Foubert-Samier A, Dupouy S, Gerdelat-Mas A, Debs R, Marquant F, De Cock VC, Rascol O, Tison F, Pavy-Le Traon A (2012) Assessment of quality of life with the multiple system atrophy health-related quality of life scale. Mov Disord 27(12):1574–1577

    Article  PubMed  Google Scholar 

  34. May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW, North American Multiple System Atrophy Study Group (2007) Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 22(16):2371–2377

    Article  PubMed  Google Scholar 

  35. Köllensperger M, Stampfer-Kountchev M, Seppi K, Geser F, Frick C, Del Sorbo F, Albanese A, Gurevich T, Giladi N, Djaldetti R, Schrag A, Low PA, Mathias CJ, Poewe W, Wenning GK (2007) Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 14(1):66–72

    Article  PubMed  Google Scholar 

  36. Brown CA, Cheng EM, Hays RD, Vassar SD, Vickrey BG (2009) SF-36 includes less Parkinson disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res 18(9):1219–1237

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work has been funded by the Ministry of Education, Science and Technological Development Republic of Serbia (project no. 175090).

Conflicts of interest

TP, MJL, IP, VS, and AT declare no conflict of interests. VK has served on the scientific advisory board for Pfizer and has received speaker honoraria from Novartis, Boehringer Ingelheim, Pfizer, Hemofarm-Stada, and GlaxoSmithKline; and VK receives research support from the Ministry of Education, Science and Technological Development of the Republic of Serbia (project no. 175090). He also received research grants from Hemopharm-Stada, Pharmaswiss, Boehringer Ingelheim, Lundbeck, Novartis, Glaxo, and Bayer.

Ethical standard

The research presented in this study was approved by local Ethics Committees, and written informed consent was obtained from each patient prior to their inclusion in this study. The authors declare that they acted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Author information

Authors and Affiliations

  1. Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Višegradska 26A, Belgrade, 11000, Serbia

    Tatjana Pekmezović

  2. Institute of Neurology, Clinical Centre of Serbia, Faculty of Medicine, School of Medicine, University of Belgrade, Ul. Dr Subotića 6, 11000, Belgrade, Serbia

    Milica Ječmenica-Lukić, Igor Petrović, Vladana Špica, Aleksandra Tomić & Vladimir S. Kostić

Authors
  1. Tatjana Pekmezović
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Milica Ječmenica-Lukić
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Igor Petrović
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vladana Špica
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aleksandra Tomić
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vladimir S. Kostić
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vladimir S. Kostić.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pekmezović, T., Ječmenica-Lukić, M., Petrović, I. et al. Quality of life in patients with progressive supranuclear palsy: one-year follow-up. J Neurol 262, 2042–2048 (2015). https://doi.org/10.1007/s00415-015-7815-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-015-7815-3

Keywords

Search

Navigation